🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementPancreatitis risk assessment — pooled safety analysis Page 2

Pancreatitis risk assessment — pooled safety analysis

Dr.MetabolicMD Thu, Mar 12, 2026 at 2:11 AM 15 replies 291 viewsPage 2 of 3
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Mar 12, 2026 at 5:01 AM#6

Excellent points all around. To summarize the red flags that should prompt immediate evaluation:

  • Severe epigastric pain (upper middle/left abdomen) radiating to the back
  • Pain that is constant and worsening over hours, not intermittent
  • Nausea and vomiting accompanying the severe pain
  • Pain that worsens after eating and is not relieved by antacids
  • Fever with abdominal pain

If you experience this constellation, go to the ER. They will check lipase levels and do imaging. But I want to echo — in 15 years of practice, I have had exactly two patients develop pancreatitis on GLP-1 RAs, both had pre-existing risk factors (one had gallstones, one had significant alcohol use). It is genuinely rare.

Contraindications for GLP-1 RAs related to pancreatic risk: personal history of pancreatitis is listed as a precaution (not absolute contraindication) in prescribing information. Discuss with your provider.

43 20LipidDoc_ATL, BariatricNurseD, MASHdoc_SA and 40 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Mar 12, 2026 at 5:18 AM#7

Thank you all so much. I feel like I can breathe again. The data really helps — <0.2% is very different from how the article my friend sent made it sound. I have no history of pancreatitis, don't drink, and don't have gallstones. I'm going to keep taking my tirzepatide and stop googling at 2am. 🙃

15 24DadBodDave, AmyNC_wife, SkepticalSean and 12 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Fatigue on semaglutide — caloric deficit vs direct drug effect25 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register